methylphenidate has been researched along with Tics in 13 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Tics: Habitual, repeated, rapid contraction of certain muscles, resulting in stereotyped individualized actions that can be voluntarily suppressed for only brief periods. They often involve the face, vocal cords, neck, and less often the extremities. Examples include repetitive throat clearing, vocalizations, sniffing, pursing the lips, and excessive blinking. Tics tend to be aggravated by emotional stress. When frequent they may interfere with speech and INTERPERSONAL RELATIONS. Conditions which feature frequent and prominent tics as a primary manifestation of disease are referred to as TIC DISORDERS. (From Adams et al., Principles of Neurology, 6th ed, pp109-10)
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, our findings suggest the association between 5-HTTLPR polymorphism and the occurrence of tics and nail-biting as an adverse event of methylphenidate." | 9.20 | Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder. ( Cheon, KA; Kim, EJ; Park, SY, 2015) |
| "Atomoxetine and OROS methylphenidate were successfully used concomitantly in a 10-year-old boy suffering from attention-deficit/hyperactivity disorder (ADHD) with comorbid bipolar disorder and Tourette syndrome (TS)." | 7.73 | Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome. ( Benarroch, F; Gross-Tsur, V; Jaworowski, S, 2006) |
| "The authors explored genetic moderators of symptom reduction and side effects in methylphenidate-treated preschool-age children diagnosed with attention-deficit/hyperactivity disorder (ADHD)." | 6.72 | Pharmacogenetics of methylphenidate response in preschoolers with ADHD. ( Abikoff, H; Chuang, S; Cunningham, C; Davies, M; Ghuman, J; Greenhill, L; Kastelic, E; Kollins, S; McCRACKEN, J; McGOUGH, J; Moyzis, R; Posner, K; Riddle, M; Shigawa, S; Skrobala, A; Swanson, J; Vitiello, B; Wigal, S; Wigal, T, 2006) |
| "This study analyzes the incidence of tics reported across five studies of children with ADHD who received methylphenidate (MPH)-based therapy as part of the clinical development program for once-daily OROS MPH (CONCERTA McNeil Consumer & Specialty Pharmaceuticals, Fort Washington, PA)." | 6.71 | Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. ( Co-Chien, H; Faraone, SV; Lynch, J; Palumbo, D; Spencer, T, 2004) |
| " However, our findings suggest the association between 5-HTTLPR polymorphism and the occurrence of tics and nail-biting as an adverse event of methylphenidate." | 5.20 | Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder. ( Cheon, KA; Kim, EJ; Park, SY, 2015) |
| "Atomoxetine and OROS methylphenidate were successfully used concomitantly in a 10-year-old boy suffering from attention-deficit/hyperactivity disorder (ADHD) with comorbid bipolar disorder and Tourette syndrome (TS)." | 3.73 | Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome. ( Benarroch, F; Gross-Tsur, V; Jaworowski, S, 2006) |
| "Behavioral reinforcement of tic suppression resulted in lower rates of tics compared to baseline, but dMPH did not enhance this suppression." | 2.75 | Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder. ( Bauer, CC; Brandt, BC; Castellanos, FX; Coffey, BJ; Conelea, C; Howard, J; Kemp, JJ; Lawrence, ZE; Lipinski, CM; Lyon, GJ; Samar, SM; Trujillo, MR; Woods, D, 2010) |
| "The authors explored genetic moderators of symptom reduction and side effects in methylphenidate-treated preschool-age children diagnosed with attention-deficit/hyperactivity disorder (ADHD)." | 2.72 | Pharmacogenetics of methylphenidate response in preschoolers with ADHD. ( Abikoff, H; Chuang, S; Cunningham, C; Davies, M; Ghuman, J; Greenhill, L; Kastelic, E; Kollins, S; McCRACKEN, J; McGOUGH, J; Moyzis, R; Posner, K; Riddle, M; Shigawa, S; Skrobala, A; Swanson, J; Vitiello, B; Wigal, S; Wigal, T, 2006) |
| "OROS methylphenidate HCL (MPH) is a recently developed long-acting stimulant medication used to treat attention-deficit/hyperactivity disorder (ADHD)." | 2.71 | A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. ( Black, DO; Conlon, C; Newcorn, JH; Pearl, PL; Robb, AS; Sarampote, CS; Seymour, KE; Stein, MA; Waldman, ID, 2003) |
| "This study analyzes the incidence of tics reported across five studies of children with ADHD who received methylphenidate (MPH)-based therapy as part of the clinical development program for once-daily OROS MPH (CONCERTA McNeil Consumer & Specialty Pharmaceuticals, Fort Washington, PA)." | 2.71 | Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. ( Co-Chien, H; Faraone, SV; Lynch, J; Palumbo, D; Spencer, T, 2004) |
| "Children with attention-deficit/hyperactivity disorder (ADHD; n = 282), all subtypes, ages 6 to 12 years, were randomized to placebo (n = 90), immediate-release methylphenidate (IR MPH) 3 times a day (tid; dosed every 4 hours; n = 97), or OROS MPH once a day (qd; n = 95) in a double-blind, 28-day trial." | 2.70 | Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. ( Atkins, M; August, G; Bukstein, O; Greenhill, LL; McBurnett, K; Palumbo, D; Pelham, W; Swanson, J; Wilens, T; Wolraich, ML, 2001) |
| "Clinical practice currently restricts the use of psychostimulant medications in children with tics or a family history of tics for fear that tics will develop or worsen as a side effect of treatment." | 2.52 | Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials. ( Bloch, MH; Cohen, SC; Coughlin, CG; Ferracioli-Oda, E; Leckman, JF; Mulqueen, JM; Stuckelman, ZD, 2015) |
| "Clonidine was associated with markedly higher clinical efficacy vs." | 1.91 | Efficacy of clonidine in the treatment of children with tic disorder co-morbid with attention deficit hyperactivity disorder. ( Hu, B; Huang, XH; Wang, GL; Yuan, Y; Zeng, KD; Zhang, W, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Zeng, KD | 1 |
| Wang, GL | 1 |
| Yuan, Y | 1 |
| Zhang, W | 1 |
| Huang, XH | 1 |
| Hu, B | 1 |
| Espadas, M | 1 |
| Insa, I | 1 |
| Chamorro, M | 1 |
| Alda-Diez, JA | 1 |
| Cohen, SC | 1 |
| Mulqueen, JM | 1 |
| Ferracioli-Oda, E | 1 |
| Stuckelman, ZD | 1 |
| Coughlin, CG | 1 |
| Leckman, JF | 1 |
| Bloch, MH | 1 |
| Park, SY | 1 |
| Kim, EJ | 1 |
| Cheon, KA | 1 |
| Lyon, GJ | 1 |
| Samar, SM | 1 |
| Conelea, C | 1 |
| Trujillo, MR | 1 |
| Lipinski, CM | 1 |
| Bauer, CC | 1 |
| Brandt, BC | 1 |
| Kemp, JJ | 1 |
| Lawrence, ZE | 1 |
| Howard, J | 1 |
| Castellanos, FX | 1 |
| Woods, D | 1 |
| Coffey, BJ | 1 |
| Pringsheim, T | 1 |
| Stein, MA | 1 |
| Sarampote, CS | 1 |
| Waldman, ID | 1 |
| Robb, AS | 1 |
| Conlon, C | 1 |
| Pearl, PL | 1 |
| Black, DO | 1 |
| Seymour, KE | 1 |
| Newcorn, JH | 1 |
| Palumbo, D | 2 |
| Spencer, T | 1 |
| Lynch, J | 1 |
| Co-Chien, H | 1 |
| Faraone, SV | 1 |
| Robertson, MM | 1 |
| Jaworowski, S | 1 |
| Benarroch, F | 1 |
| Gross-Tsur, V | 1 |
| McGOUGH, J | 1 |
| McCRACKEN, J | 1 |
| Swanson, J | 2 |
| Riddle, M | 1 |
| Kollins, S | 1 |
| Greenhill, L | 1 |
| Abikoff, H | 1 |
| Davies, M | 1 |
| Chuang, S | 1 |
| Wigal, T | 1 |
| Wigal, S | 1 |
| Posner, K | 1 |
| Skrobala, A | 1 |
| Kastelic, E | 1 |
| Ghuman, J | 1 |
| Cunningham, C | 1 |
| Shigawa, S | 1 |
| Moyzis, R | 1 |
| Vitiello, B | 1 |
| Wolraich, ML | 1 |
| Greenhill, LL | 1 |
| Pelham, W | 1 |
| Wilens, T | 1 |
| Atkins, M | 1 |
| McBurnett, K | 1 |
| Bukstein, O | 1 |
| August, G | 1 |
| Kurlan, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Methylphenidate (MPH) and Non-invasive Brain Stimulation (tDCS) on Inhibitory Control Children With Attention-Deficit/Hyperactivity Disorder (ADHD)[NCT04964427] | 26 participants (Actual) | Interventional | 2021-02-08 | Completed | |||
| Sleep and Tolerability of Extended Release Dexmethylphenidate vs. Mixed Amphetamine Salts: A Double Blind, Placebo Controlled Study (SAT STUDY)[NCT00393042] | Phase 3 | 77 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Dose Response Pharmacogenetic Study of ADHD[NCT00663442] | Phase 4 | 48 participants (Actual) | Interventional | 1999-12-31 | Completed | ||
| Methylphenidate Efficacy and Safety in ADHD Preschoolers[NCT00018863] | Phase 3 | 165 participants | Interventional | 2001-04-01 | Completed | ||
| Multicenter Study Comparing the Efficacy and Safety of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD[NCT00269802] | Phase 3 | 0 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill. (NCT00393042)
Timeframe: 8-10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Adderall XR - Placebo | 4.26 |
| Adderall XR - 10 mg | 4.09 |
| Adderall XR - 20 mg | 3.48 |
| Adderall XR - 25/30 mg | 3.56 |
| Focalin XR - Placebo | 4.24 |
| Focalin - 10 mg | 4.24 |
| Focalin XR - 20 mg | 3.63 |
| Focalin XR - 25/30 mg | 3.55 |
Actigraphs (AW64 series) were worn each night and were used to assess participant's sleep patterns in their natural home environment. These computerized wristwatch-like devices collect data generated by movements. They are minimally invasive and allow sleep to be recorded reliably without interfering with the family's routine. One-minute epochs were used to analyze actigraphic sleep sata. Bedtimes and wake times were reported for each participant using sleep logs, and these times were used as the start and end times for the analyses. For each 1-min epoch, the total sum of activity counts were computed. If they exceeded a threshold (threshold sensitivity value = mean score in active period/45), then the epoch was considered waking. If it fell below that threshold, then it was considered sleep.The data for Adderall XR and Focalin XR was combined to look at the cumulative effects that medication has on sleep. (NCT00393042)
Timeframe: 8-10 weeks
| Intervention | minutes (Mean) |
|---|---|
| Placebo | 459.6 |
| 10mg of Either Focalin XR or Adderall XR | 446.7 |
| 20 mg of Either Focalin XR or Adderall XR | 432.17 |
| 25/30mg of Either Focalin XR or Adderall XR | 425.5 |
| Adderall XR All Dose Levels | 438.82 |
| Focalin XR All Dose Levels | 443.2 |
Measures the severity of Total ADHD symptoms, Inattention and Hyperactivity/Impulsive symptoms. The Inattention and Hyperactivity/Impulsive symptoms can range from 0 to 27 each, with a higher score reflecting more severe ADHD symptoms. The total score is calculated by summing the inattention and Hyperactivity/Impulsive subscales. The total score can range from 0 to 54 with a higher score reflecting more severe ADHD symptoms. (NCT00393042)
Timeframe: completed weekly over 8-10 weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Inattention Symptom Subscale Scores | Hyperactivity/Impulsivity Symptom subscale scores | Total Symptoms scores | |
| Adderall XR - 10 mg | 6.40 | 10.78 | 27.15 |
| Adderall XR - 20 mg | 12.2 | 7.92 | 20.12 |
| Adderall XR - 25/30mg | 12.74 | 7.67 | 20.40 |
| Adderall XR - Placebo | 16.61 | 11.41 | 28.02 |
| Focalin XR - 10 mg | 17.51 | 10.84 | 28.35 |
| Focalin XR - 20 mg | 13.33 | 8.49 | 21.82 |
| Focalin XR - 25/30mg | 12.11 | 8.49 | 20.41 |
| Focalin XR - Placebo | 17.31 | 13.24 | 30.58 |
Three variations of the DAT 1 gene were observed, the 9/9 allele, the 9/10 allele and the 10/10 allele. The ADHD Rating Scale (ADHD-RS) and Clinical Global Impressions - Severity (CGI-S) measures were used to evaluate how the DAT 1 gene allele type altered the efficacy of the medication. The DAT 1 genotype did not predict differential response to Focalin XR or Adderall XR so the dose levels of each drug was combined to examine how the genotype interacted with the dose level. The ADHD-RS evaluates the severity of the participant's ADHD symptoms and includes two subscales: Inattention and Hyperactivity/Impulsivity. Both subscale scores range from 0 to 27 with a higher score representing more severe symptoms. The subscales are summed to calculate the total score which can range from 0 to 54. The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill. (NCT00393042)
Timeframe: 8-10 weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| ADHD-RS Inattention subscale score | ADHD-RS Hyperactivity/Impulsivity subscale score | ADHD-RS total score | CGI-S score | |
| 10/10 Allele: 10 mg of Adderall XR | 16.13 | 9.63 | 25.77 | 4.07 |
| 10/10 Allele: 10 mg of Focalin XR | 16.56 | 10.63 | 27.19 | 4.19 |
| 10/10 Allele: 20 mg of Adderall XR | 9.36 | 7.07 | 16.43 | 3.21 |
| 10/10 Allele: 20 mg of Focalin XR | 12.56 | 8.41 | 20.96 | 3.52 |
| 10/10 Allele: 25/30 mg of Adderall XR | 11.96 | 7.50 | 19.46 | 3.54 |
| 10/10 Allele: 25/30mg of Focaling XR | 11.15 | 8.65 | 19.81 | 3.31 |
| 10/10 Allele: Placebo of Adderall XR | 15.07 | 11.87 | 26.93 | 4.17 |
| 10/10 Allele: Placebo of Focalin XR | 16.44 | 13.74 | 30.19 | 4.15 |
| 9/10 Allele: 10 mg of Adderall XR | 16.27 | 10.67 | 26.80 | 4.07 |
| 9/10 Allele: 10 mg of Focalin XR | 16.93 | 8.27 | 25.20 | 4.27 |
| 9/10 Allele: 20 mg of Adderall XR | 15.86 | 8.36 | 24.21 | 3.71 |
| 9/10 Allele: 20 mg of Focalin XR | 13.36 | 6.73 | 20.09 | 3.58 |
| 9/10 Allele: 25/30 mg of Adderall XR | 13.43 | 6.43 | 19.86 | 3.50 |
| 9/10 Allele: 25/30 mg of Focalin XR | 13.70 | 7.00 | 20.70 | 3.90 |
| 9/10 Allele: Placebo of Adderall XR | 18.64 | 9.36 | 28.00 | 4.36 |
| 9/10 Allele: Placebo of Focalin XR | 18.08 | 8.92 | 27.08 | 4.31 |
| 9/9 Allele: 10 mg of Adderall XR | 18.83 | 18.33 | 37.17 | 4.33 |
| 9/9 Allele: 10 mg of Focalin XR | 22.20 | 17.40 | 39.60 | 4.60 |
| 9/9 Allele: 20 mg Adderall XR | 19.00 | 14.80 | 33.80 | 4.80 |
| 9/9 Allele: 20 mg of Focalin XR | 16.75 | 14.00 | 30.75 | 4.50 |
| 9/9 Allele: 25/30 mg of Focalin XR | 12.50 | 9.00 | 24.00 | 4.00 |
| 9/9 Allele: 25/30mg of Adderall XR | 15.40 | 10.40 | 25.80 | 4.00 |
| 9/9 Allele: Placebo of Adderall XR | 18.60 | 12.80 | 31.40 | 4.40 |
| 9/9 Allele: Placebo of Focalin XR | 19.33 | 17.33 | 36.67 | 4.67 |
Actigraphs (AW64 series) were worn each night and were used to assess participant's sleep patterns in their natural home environment. These computerized wristwatch-like devices collect data generated by movements. They are minimally invasive and allow sleep to be recorded reliably without interfering with the family's routine. One-minute epochs were used to analyze actigraphic sleep sata. Bedtimes and wake times were reported for each participant using sleep logs, and these times were used as the start and end times for the analyses. For each 1-min epoch, the total sum of activity counts were computed. If they exceeded a threshold (threshold sensitivity value = mean score in active period/45), then the epoch was considered waking. If it fell below that threshold, then it was considered sleep. The data for Adderall XR and Focalin XR was combined to look at the cumulative effects that medication has on sleep. (NCT00393042)
Timeframe: 8-10 weeks
| Intervention | HHMM.SS (Mean) | |
|---|---|---|
| Sleep start time | Sleep End time | |
| 10mg of Either Focalin XR or Adderall XR | 2304 | 0728 |
| 20mg of Either Focalin XR or Adderall XR | 2319 | 0735 |
| 25/30mg of Either Focalin XR or Adderall XR | 2325 | 0732 |
| Adderall XR All Dose Levels | 2309 | 0735 |
| Focalin XR All Dose Levels | 2309 | 0734 |
| Placebo | 2249 | 0742 |
The WFIRS consists of 50 questions where respondents are asked to rate their child's functional impairment. The items of the WFIRS are scored on a four point Likert-type rating scale: 0 (never or not at all), 1 (sometimes or somewhat), 2 (often or much) or 3 (very often or very much) and aggregated to produce six domain scores: Family (ranges between 0-24), Learning or School (ranges between 0-33), Self-Concept (ranges between 0-15), Social Activities (ranges between 0-27), Life Skills (ranges between 0-36), and Risky Activities (ranges between 0-42). The subscales are scored by summing the responses in the subsection. The Total score is the sum of all the responses and it ranges between 0-150. The higher the score in each of the subscales the more impairment is recorded, this is also true for the total score. (NCT00393042)
Timeframe: 8-10 weeks
| Intervention | units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Family subscale score | Learning subscale score | Life skills subscale score | Self-concept subscale score | Social activities subscale score | Risky activities subscale score | Total score | |
| Adderall XR - 10 mg | 7.02 | 8.75 | 7.91 | 1.59 | 3.91 | 1.94 | 31.06 |
| Adderall XR - 20 mg | 6.35 | 6.86 | 7.44 | 1.42 | 2.98 | 2.24 | 27.32 |
| Adderall XR - 25/30mg | 6.70 | 6.21 | 7.34 | 1.06 | 3.06 | 1.68 | 26.23 |
| Adderall XR - Placebo | 6.72 | 6.74 | 7.43 | 1.11 | 3.51 | 2.19 | 27.70 |
| Focalin XR - 10 mg | 7.35 | 9.25 | 7.65 | 1.19 | 3.85 | 1.96 | 31.13 |
| Focalin XR - 20 mg | 6.50 | 7.54 | 8.30 | 1.33 | 3.54 | 1.78 | 29.20 |
| Focalin XR - 25/30mg | 6.50 | 7.39 | 7.60 | 1.31 | 3.17 | 1.67 | 27.45 |
| Focalin XR - Placebo | 7.39 | 9.30 | 8.30 | 1.25 | 3.73 | 1.91 | 20.91 |
3 reviews available for methylphenidate and Tics
| Article | Year |
|---|---|
[Side effects of methylphenidate in children and the young].
Topics: Adolescent; Anorexia; Attention Deficit Disorder with Hyperactivity; Bone Diseases, Developmental; C | 2018 |
Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials.
Topics: Adolescent; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimu | 2015 |
Attention deficit hyperactivity disorder, tics and Tourette's syndrome: the relationship and treatment implications. A commentary.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2006 |
6 trials available for methylphenidate and Tics
| Article | Year |
|---|---|
Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Alleles; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2015 |
Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2010 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2003 |
Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2004 |
Pharmacogenetics of methylphenidate response in preschoolers with ADHD.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child, Preschool; | 2006 |
Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
Topics: Appetite; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; D | 2001 |
4 other studies available for methylphenidate and Tics
| Article | Year |
|---|---|
Efficacy of clonidine in the treatment of children with tic disorder co-morbid with attention deficit hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; | 2023 |
Psychopharmacology for the clinician: management of comorbid Tourette syndrome and attention-deficit/hyperactivity disorder: are psychostimulants an option?
Topics: Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2012 |
Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2006 |
Methylphenidate to treat ADHD is not contraindicated in children with tics.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Female | 2002 |